Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Provectus Biopharmaceuticals Inc (OP: PVCT )

0.1199 +0.0062 (+5.45%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 308,351
Open 0.1111
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1137
Today's Range 0.1090 - 0.1200
52wk Range 0.0445 - 0.2245
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PVCT Stock Earnings: Provectus Reported Results for Q2 2024
Provectus just reported results for the second quarter of 2024. 
Via InvestorPlace
PVCT Stock Earnings: Provectus Reported Results for Q1 2024
Provectus just reported results for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+14.41%
+14.41%
1 Month
+12.06%
+12.06%
3 Month
+9.10%
+9.10%
6 Month
-36.29%
-36.29%
1 Year
-11.19%
-11.19%

More News

Read More
PVCT Stock Earnings: Provectus Reported Results for Q4 2023
Via InvestorPlace
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
Via Benzinga
Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.